Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma
- First Posted Date
- 2016-04-15
- Last Posted Date
- 2016-07-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 89
- Registration Number
- NCT02739594
A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Participants and Women With Early Breast Cancer (EBC)
- First Posted Date
- 2016-04-14
- Last Posted Date
- 2018-06-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 88
- Registration Number
- NCT02738970
- Locations
- 🇳🇿
Christchurch Clinical Studies Trust, Christchurch, New Zealand
🇳🇿Auckland Clinical Studies, Auckland, New Zealand
Expanded Access Study With Peginterferon Alfa-2a (Pegasys) in Participants With Chronic Myelogenous Leukemia (CML)
- First Posted Date
- 2016-04-13
- Last Posted Date
- 2016-09-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 41
- Registration Number
- NCT02736721
Efficacy, and Safety Study of Optimized Background Antiretroviral Regimen (OB) in Combination With Enfuvirtide in the Treatment-Experienced Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection
Phase 3
Completed
- Conditions
- HIV Infections
- Interventions
- Drug: EnfuvirtideDrug: Optimized background antiretroviral regimen (OB)
- First Posted Date
- 2016-04-11
- Last Posted Date
- 2016-04-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 84
- Registration Number
- NCT02733419
A Study of Pegylated Interferon (PEG-IFN) Alfa-2a (Pegasys) in Participants With Chronic Hepatitis D (CHD)
Phase 3
Completed
- Conditions
- Hepatitis D, Chronic
- Interventions
- Drug: Pegylated Interferon (PEG-IFN) alfa-2a
- First Posted Date
- 2016-04-08
- Last Posted Date
- 2016-08-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 31
- Registration Number
- NCT02732639
A Study of Peginterferon Alfa-2a With or Without Ribavirin in Participants With Chronic Hepatitis D (CHD)
Phase 2
Completed
- Conditions
- Hepatitis D, Chronic
- Interventions
- First Posted Date
- 2016-04-07
- Last Posted Date
- 2016-07-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 12
- Registration Number
- NCT02731131
Human Epidermal Growth Factor Receptor 2 (HER-2) Status in Gastric and Gastro-Esophageal Junction (GEJ) Carcinoma
Completed
- Conditions
- Gastric Cancer, Gastroesophageal Junction Cancer
- Interventions
- Biological: Trastuzumab
- First Posted Date
- 2016-04-07
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 420
- Registration Number
- NCT02731313
A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 1
Completed
- Conditions
- Lymphoma
- Interventions
- First Posted Date
- 2016-04-06
- Last Posted Date
- 2020-12-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 36
- Registration Number
- NCT02729896
- Locations
- 🇵🇱
Instytut Hematologii i Transfuzjologii; Klinika Zaburzeń Hemostazy i Chorób Wewnętrznych, Warsaw, Poland
🇺🇸UCLA, Los Angeles, California, United States
🇺🇸University Miami, Miami, Florida, United States
A Quality of Life Study of Peginterferon-Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C and Persistently Normal Alanine Transaminase (ALT) Levels
- First Posted Date
- 2016-04-01
- Last Posted Date
- 2016-08-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 114
- Registration Number
- NCT02726022
A Study of Ocrelizumab in Participants With Follicular Non-Hodgkin's Lymphoma (NHL)
- First Posted Date
- 2016-03-30
- Last Posted Date
- 2016-03-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 48
- Registration Number
- NCT02723071
© Copyright 2025. All Rights Reserved by MedPath